SusanFSlovinMD

PubMed

• Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
  de Almeida, D., Cohn, E., Baser, R., Anderson, J., Danila, D., Morris, M., Slovin, S., Abida, W., Scher, H., Autio, K.> ;Journal of Immunotherapy and Precision Oncology. 2023 Nov 1
• 2 citations
  Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review.
  Adam J Nelson, Renato D Lopes, Hwanhee Hong, Kaiyuan Hua, Susan Slovin, Sean Tan, Jan Nilsson, Deepak L Bhatt, Shaun G Goodman, Christopher P Evans, Noel W Clarke, Nea...> ;JACC. Cardiooncology. 2023 Oct 1
• Genomic Portraits: Reflections into a Tumor's Response to Therapy.
  Susan F Slovin> ;Clinical Cancer Research. 2023 Nov 1
• Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
  Susan F Slovin, Karen Knudsen, Susan Halabi, Renee de Leeuw, Ayesha Shafi, Praneet Kang, Steven Wolf, Bin Luo, Anuradha Gopalan, Tracy Curley, Mark Fleming, Ana Molina...> ;Journal of Clinical Oncology. 2023 Nov 10
• 2 citations
  Immunotherapy in the Treatment of Localized Genitourinary Cancers.
  Andrea Necchi, Susan F Slovin, Joshua J Meeks, Sumanta K Pal, Lawrence H Schwartz, Richard S P Huang, Roger Li, Brandon Manley, Jad Chahoud, Jeffrey S Ross, Philippe E...> ;JAMA Oncology. 2023 Oct 1
• An AI Predictive Model to Determine Who Benefits from ADT with Radiation: Working Smarter, Not Harder.
  Slovin, S.> ;NEJM Evidence. 2023 Aug 1
• 1 citations
  Immunotherapy combinations for metastatic castration-resistant prostate cancer - failed trials and future aspects.
  Susan F Slovin> ;Current Opinion in Urology. 2023 Sep 1
• 6 citations
  Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.
  Jamie M Sperger, Kyle T Helzer, Charlotte N Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R Kaufmann, David J Niles, Erika Heninger, Nicholas R Rydzewski, Liguo Wan...> ;Clinical Cancer Research. 2023 Jun 13
• 2 citations
  Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained ...
  Kenneth Cornetta, Jing Yao, Kimberley House, Lisa Duffy, Prasad S Adusumilli, Rachel Beyer, Claire Booth, Malcolm Brenner, Kevin Curran, Bambi Grilley, Helen Heslop, C...> ;Molecular Therapy. 2023 Mar 1
• 8 citations
  Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
  Hong Truong, Kelsey Breen, Subhiksha Nandakumar, Daniel D Sjoberg, Yelena Kemel, Nikita Mehta, Andrew T Lenis, Peter A Reisz, Jessica Carruthers, Nicole Benfante, Vija...> ;European Urology. 2023 Jan 1
• 3 citations
  Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
  Niamh M Keegan, Samantha E Vasselman, Ethan S Barnett, Barbara Nweji, Emily A Carbone, Alexander Blum, Michael J Morris, Dana E Rathkopf, Susan F Slovin, Daniel C Dani...> ;The Prostate. 2022 Aug 1
• 3 citations
  Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prosta...
  Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath,...> ;European Urology Open Science. 2021 Dec 1
• 25 citations
  Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
  Konrad H. Stopsack, Subhiksha Nandakumar, Kanika Arora, Bastien Nguyen, Samantha E. Vasselman, Barbara Nweji, Sean McBride, Michael J. Morris, Dana E. Rathkopf, Susan ...> ;Clinical Cancer Research. 2021 Oct 19
• 45 citations
  Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
  Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, P. Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson,...> ;Circulation. 2021 Oct 19
• 14 citations
  RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.
  Anja van de Stolpe, Wim Verhaegh, Jean-Yves Blay, Cynthia X. Ma, Patrick Pauwels, Mark D. Pegram, Hans Prenen, Dirk De Ruysscher, Nabil F. Saba, Susan F. Slovin, Karen...> ;Frontiers in Genetics. 2021 Feb 1
• 3 citations
  Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
  E. David Crawford, Gerald L. Andriole, Stephen J. Freedland, Marc B. Garnick, Leonard G. Gomella, Jonathan Henderson, Celestia Tia Higano, Andrew Karim Kader, Christop...> ;The Canadian Journal of Urology. 2020 Oct 1
• Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype
  Susan F. Slovin> ;The Urologic Clinics of North America. 2020 Sep 10
• 27 citations
  Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
  Karen A. Autio, Christopher A. Klebanoff, David Schaer, John S. Kauh, Susan F. Slovin, Matthew Adamow, Victoria S. Blinder, Manisha Brahmachary, Michelle Carlsen, Eliz...> ;Clinical Cancer Research. 2020 Aug 26
• 89 citations
  Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
  Jose Mauricio Mota, Ethan Barnett, Jones T. Nauseef, Bastien Nguyen, Konrad H. Stopsack, Andreas Wibmer, Jessica Flynn, Glenn Heller, Daniel C. Danila, Dana E. Rathkop...> ;JCO Precision Oncology. 2020 Apr 16
• The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few.
  Susan F. Slovin> ;Immunotherapy. 2020 Mar 16
• 8 citations
  Immunotherapy for castration-resistant prostate cancer: has its time arrived?
  Susan F. Slovin> ;Expert Opinion on Biological Therapy. 2020 Mar 5
• 27 citations
  Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
  Chiara Melloni, Susan F. Slovin, Allan Blemings, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Konstantin Zubovskiy, Tine Kold Olesen, Klaus Du...> ;JACC. Cardiooncology. 2020 Mar 1
• 20 citations
  A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
  Deaglan Joseph McHugh, Jay Chudow, Mia DeNunzio, Susan F. Slovin, Daniel C. Danila, Michael J. Morris, Howard I. Scher, Dana E. Rathkopf> ;Clinical Genitourinary Cancer. 2020 Jan 11
• 2 citations
  Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: Can an Agnostic Become a Believer?
  Susan F. Slovin> ;Journal of Clinical Oncology. 2020 Feb 10
• 2 citations
  Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?
  Susan F. Slovin> ;European Urology. 2020 Mar 1
• Join now to see all

Journal Articles

• Biomarkers for Immunotherapy in Genitourinary Malignancies  
  Slovin SF, Urologic Oncology: Seminars and Original Investigations, 1/16/2015
• Androgen Deprivation Therapy for Prostate Cancer – Friend or Foe to the Psyche?  
  Slovin SF, J Clin Onc, 1/11/2015
• Immunotherapeutic Approaches in Prostate Cancer, Combinations, and Clinical Integration, ASCO Educational Book  
  Slovin SF, Am Soc Clin Oncol, 1/1/2015
• Metabolism and Pharmacokinetics of Radium-223 in Prostate Cancer  
  Yeku O and Slovin SF, Expert Opinion on Drug Metabolism and Toxicology, 1/1/2015
• Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival  
  De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh ..., Int J Cancer, 1/1/2015
• SIDEBAR: Melanoma and Prostate Cancer: Two Sides of One Coin?  
  Slovin SF, ASCO Post, 1/15/2014
• Ipilimumab Alone or in Combination with Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: Results from an Open-Label, Multi-Center Phase 1/2 Study  
  Slovin SF, Higano T, Hamid O, Tejwani S, Harzstark A, Alumkal J, Scher H, Chin K, Gagnier P, McHenry M, Beer T, Ann Onc, 1/1/2013
• Repetitively Dosed Docetaxel and 153Samarium-EDTMP as an Anti-Tumor Strategy for Metastatic Castration-Resistant Prostate Cancer  
  Autio KA, KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ, et al, Cancer, 1/1/2013
• Emerging treatments in the management of prostate cancer: Biomarker validation and endpoints for immunotherapy clinical trial design  
  Slovin SF, ImmunoTargets and Therapy, 1/1/2013
• Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where is the future?  
  Snyder A, Tepper J, and Slovin SF, Sem Onc, 1/1/2013
• A phase I/II study of AGS-PSCA for castration-resistant prostate cancer  
  Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA, Ann Onc, 1/1/2012
• Augmenting advance care planning in poor prognosis cancer with a video decision aid: A preintervention-postintervention study  
  Volandes AE, Levin TT, Slovin S, Cavajal RD, O’Reilly EM, Keohan ML, Theodoulou M, Dickler M, Gerecitano JF, Morris M, Epstein AS, Naka-Blackstone A, Walker-Corkery ES..., Cancer, 1/1/2012
• Chemotherapy and immunotherapy combination in advanced prostate cancer  
  Slovin SF, Clin Adv in Hematol Onc, 1/1/2012
• Immunotherapy and cancer – making the past prologue  
  Slovin SF, Clin Invest, 1/1/2012
• Toward maximizing immunotherapy in metastatic castration resistant prostate cancer - rationale for combinatorial approaches using chemotherapy  
  Slovin SF, Frontiers in Genitourinary Oncology, 1/1/2012
• Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer  
  Rathkopf D, Liu G , Carducci MA, Eisenberger MA, Anand A, Morris M, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NGE, Cheng S, Gan J, Gottardis MM, Obermeier M, Red..., Clin Cancer Res, 1/1/2011
• Immunogenicity of Cancer Vaccines: QS-21 as an immune adjuvant  
  Gin D and Slovin SF, Current Drug Therapy, 1/1/2011
• Are we trumping bone disease in prostate cancer?  
  Slovin SF, Oncology, 1/1/2011
• Seeking informed consent to Phase 1 Cancer Clinical Trials: Identifying Oncologists’ Communication Strategies  
  Brown R, Bylund C, Siminoff, L, Slovin SF, Psycho-Oncology, 1/1/2011
• Caring for your bones when you have prostate cancer  
  Slovin SF, Coping, 1/1/2010
• clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?  
  Slovin SF, Immunotherapy, 1/1/2010
• Tumor vasculature expression of B7-H3 predicts survival in ovarian carcinomas  
  Zang X, Sullivan PS, Soslow RA, Waitz P, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin S, Wei, J, Spriggs DR, Dupont J, Allison JP, Modern Pathology, 1/1/2010
• Anti-Epidermal Growth Factor Receptor Monoclonal Antibody [Cetuximab (C225)] Plus Doxorubicin for Treatment of Castrate Metastatic Prostate Cancer  
  Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher H, Clin Genitourinary Onc, 1/1/2009
• Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research  
  Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Logothetis C, Scher HI, Clinical Genitourinary Cancer, 1/1/2009
• Phase I trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer  
  Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI, Eur Urol, 1/1/2009
• Join now to see all

Books/Book Chapters

• Prostate Cancer: A Multidisciplinary Approach To Diagnosis and Management 
  Chapter: mRPC: Mechanisms of hormone escape. 
  Page 310 - 320Slovin SFEditors: Dicker AP, Kelly WK, Trabulsi EJ, Zaorsky NG.Demos Medical Publishing, L.L.C., New York, NY2015
• CONNECT(R) Booklet Series/CancerCare, “Your Guide to the Latest Cancer Research and Treatments” Highlights from the 2011 Annual Meeting of the American Society of Clinical Oncology. 
  Editors: Benson, AB, Berger AM, Brem SS, Crawford, ED, Flaherty KT, Giralt SA, Jonasch E, Morgan RJ, Perez EA, Slovin S, Socinski MA, von Mehren M.CancerCare, Inc.2011
• Principles and Practice of Cancer Rehabilitation 
  Chapter: Evaluation and treatment of prostate and genitourinary Cancer 
  Page 193 - 204Morozov A and Slovin, SFEditors: Stubblefield, M.O’Dell, C. Custodio, and T. Fitzpatrick.Demos Medical Publishing, Woodbridge, CT2009
• Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas 
  Chapter: Can Effector Cells Really 'Effect' an Antitumor Response as Cancer Therapy? 
  Page 59 - 65Slovin SFEditors: Hayat, MA.Academic Press2006
• Translational and Emerging Concepts in Prostate Cancer 
  Chapter: Entry into the Cell Signaling Abyss 
  Page 75 - 85Slovin SFEditors: Kelly and Dawson.Taylor & Francis Group, LLC, New York, NY2006
• Management of Prostate Cancer: Advances and Controversies 
  Chapter: Novel therapies for PSA Progression in the Absence of Imageable Disease Following Local Therapy. 
  Page 359 - 364Slovin, SFEditors: KB Cummings.Marcel Dekker2005
• Advances in Platinum-Based chemotherapy 
  Chapter: Update of platinums in the treatment of prostate cancer 
  Page 23 - 27Slovin, SFEditors: R. Ozols.HMP Communications, LLC2001
• New Perspectives in Prostate Cancer. 
  Chapter: Immunologic targeting for the treatment of prostate cancer 
  Page 341 - 352Slovin, S.F., Livingston, P.O., Rosen, N., Sepp-Lorenzino, L., Kelly, W.K., Mendelsohn J., Scher, H.I.Editors: Belldegrun A., Kirby R, Oliver, T and Brill, M.Isis Medical Media Ltd .1998
• Role of the Environment and Pathogenesis of Leukemia and Lymphoma. Progress in Cancer Research & Therapy, vol. 27. 
  Chapter: Detection and isolation of Epstein-Barr virus in lymphocytes from patients with chronic lymphocytic leukemia (CLL). 
  Page 259 - 262Armstrong G, Longo D, Faggioni A, Ablashi D, Pearson G, Slovin SFEditors: I.T. Magrath, G.T. O'Connor, B. Ramot.Raven Press, New York, NY1984
• Springer Seminars in Immunopathology 
  Chapter: Physiology and pathology of rheumatoid factors. 
  Page 161 - 179Carson,D.A. Pasqauli,L.-L. Tsoukas, C.D. Fong, S., Slovin, S.F., Lawrance,S.K., Slaughter,L. Vaughan,J.HSpringer-Verlag1981
• Immunopathogenesis of rheumatoid arthritis 
  Chapter: Biological properties of anti-IgG antibodies. 
  Page 80 - 89Vaughan JH, Kaplan RA, Slovin SF, Carson DAEditors: G. Panayi, P.M. Johnson.1979
• Advances in Pathology, Cancer Biology: Differentiation and Carcinogenesis 
  Chapter: An introduction to affinity chromatography. 
  Page 263 - 271Parikh I and Slovin SFEditors: C. Borek, C. Fenoglio,D.W. King.1977
• Join now to see all

Abstracts/Posters

• Traversing the Glycan Pathway.
  Slovin, SF, American Society of Clinical Oncology, Chicago, IL, 1/30/2008
• Preventing Osteoporosis in the Androgen-Deprived State - Do SERMS Really Rate?
  Slovin, SF, Late Breaking Abstracts; American Assoc of Cancer Res, San Diego, CA, 1/12/2008

Lectures

• A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and car... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Prostate cancer immunotherapy: Here to stay or over and out? 
  Maimonides Medical Center, Brooklyn, NY - 1/27/2015
• Biomarkers for genitourinary malignancies: prime or choice? 
  Memorial Sloan-Kettering Cancer Center, New York, NY - 1/27/2015
• Prostate Cancer Part I: Prostate Cancer Prevention, Detection, and Treatment of Localized Disease 
  1/22/2015
• Prostate 101 
  Bates College, Lewiston, ME - 1/20/2015
• Treating Advanced Prostate Cancer – A primer for radiation oncologists 
  1/15/2015
• Castrate resistant prostate cancer: Controversies in therapeutic approaches 
  Beirut, Lebanon - 1/7/2015
• ASCO Highlights – Prostate Cancer 
  1/7/2015
• Immuotherapeutic approaches in prostate cancer, combinations and clinical integrations. 
  Chicago, IL - 1/2/2015
• Renal Cell Carcinoma and the Role of Anti-Angiogenic Therapy 
  Amann, Jordan - 1/1/2015
• New Approaches to Endocrine Treatment II: Lyase Inhibitors 
  San Francisco, CA - 1/31/2014
• Radiation-Induced Immune Modulation as Prostate Cancer therapy 
  La Jolla, CA - 1/27/2014
• Choosing Novel and Standard Prostate Cancer Treatments From a Sea of Plenty 
  Cornell Medical College, New York, NY - 1/19/2014
• Exploiting Immunomodulatory Antibodies in Prostate Cancer (New Antibodies) 
  Dallas, TX - 1/16/2014
• Prostate Cancer - Introduction to Personalized Treatment 
  Doha, Qatar - 1/11/2014
• Maximizing Immune Targeting with Combination Therapies 
  Boston, MA - 1/8/2014
• Advances in Immunotherapy for Prostate Cancer Over the Past 5 Years 
  New York, NY - 1/4/2014
• Advances in immunotherapy therapy for prostate cancer over the past 5 years 
  New York, NY - 1/4/2014
• Immunomodulation and TS-VTP in Prostate Cancer: Clinical Trial Design 
  Oxford, England - 1/4/2014
• Predictors for Metastatic Progression 
  Vail, CO - 1/22/2013
• Current State of Immunotherapy for Advanced Prostate Cancer 
  Juravinski Cancer Center, Hamilton, Ontario, Canada - 1/17/2013
• Immunotherapeutic Strategies to Augment Prostate Cancer Treatment 
  McMasters Medical Center, Hamilton, Ontario, Canada - 1/17/2013
• Advances in Immunotherapy – How to integrate into the prostate care continuum. 
  New York, NY - 1/16/2013
• Prostate Cancer Disease Overview and Current Status 
  Memorial Sloan-Kettering Cancer Center, New York, NY - 1/14/2013
• Advances in Biomarker Validation and Trial Design for Antitumor Immunotherapy. 
  Cambridge, MA - 1/13/2013
• Join now to see all

Other

• Better Bone Health for Men Living with Prostate Cancer 
  Slovin S, and Partington, EW, CANCERcare Connect TM Patient Monograph
  1/1/2005
• Cancer Immunotherapeutics - CHI Meeting (Part III) 
  Slovin, SF, IDDB Meeting Report 2
  Boston, MA - 1/20/2004
• Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety? 
  Slovin, SF, Medscape Hematology-Oncology e-Journal
  1/1/2002
• Prostate and Testicular Cancer Detection and Education Advisory Council – Report and Recommendations 
  Slovin, SF, et al, New York State Commissioner of Health report
  1/1/2002
• Join now to see all